Company Description
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company.
The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.
Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease.
Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
| Country | United States |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 56 |
| CEO | David P. Hochman |
Contact Details
Address: 150 Union Square Drive New Hope, Pennsylvania 18938 United States | |
| Phone | 646-343-9298 |
| Website | orchestrabiomed.com |
Stock Details
| Ticker Symbol | OBIO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001814114 |
| ISIN Number | US68572M1062 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| David P. Hochman | Founder, Chairman of the Board of Directors and Chief Executive Officer |
| Darren R. Sherman | Founder, President, Chief Operating Officer and Director |
| Andrew Lawrence Taylor M.B.A. | Chief Financial Officer |
| William Reed Little | Executive Vice President of Corporate Development and Strategy |
| Dr. Yuval Hay Mika D.Sc, Ph.D. | GM and Chief Technology Officer of Bioelectronic Therapies |
| Dr. George Papandreou Ph.D. | GM and Senior Vice President of Focal Therapies |
| Dr. Hans-Peter Stoll M.D., Ph.D. | Chief Clinical Officer |
| Dr. Avraham Matityahu Fischer M.D. | Senior Vice President of Medical Affairs and Innovation |
| Bob Laughner | Senior Vice President of Regulatory and Quality |
| Juan Lorenzo | Senior Vice President of Product Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 29, 2024 | 8-K | Current Report |
| Mar 27, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 27, 2024 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Mar 27, 2024 | 10-K | Annual Report |
| Mar 7, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 28, 2023 | 8-K | Current Report |
| Nov 14, 2023 | 8-K | Current Report |